Latest: FDA Approves New Biosimilar for Oncology Treatment
Pharmaceutical

FDA approves LEQEMBI IQLIK for maintenance dosing in early Alzheimer’s disease

by PharmaTimes
0 Comments
0 Mins
New subcutaneous autoinjector offers at-home treatment option for patients New subcutaneous autoinjector offers at-home treatment option for patients
Tags:
PharmaTimes
Author

PharmaTimes

Previous Post
Lilly receives UK approval for pirtobrutinib in relapsed blood cancers
Next Post
Nagaland medical students protest regularisation of 280 contractual health workers
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago